L19 TNF fusion protein - Philogen

Drug Profile

L19 TNF fusion protein - Philogen

Alternative Names: Fibromun; L19-TNF; L19TNFalpha

Latest Information Update: 03 Nov 2016

Price : $50

At a glance

  • Originator Philogen
  • Class Antineoplastics; Monoclonal antibodies; Recombinant fusion proteins; Tumour necrosis factors
  • Mechanism of Action Angiogenesis inhibitors; Immunostimulants; Tumour necrosis factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant melanoma; Sarcoma
  • Phase I Breast cancer; Solid tumours
  • No development reported Colorectal cancer

Most Recent Events

  • 28 Oct 2016 L19 TNF fusion protein - Philogen receives Orphan Drug status for Soft tissue sarcoma in European Union
  • 21 Jan 2016 Efficacy data from a phase II trial in Malignant melanoma released by Philogen
  • 25 Aug 2015 Phase-II development for Malignant melanoma (Combination therapy) is ongoing in Italy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top